Effectiveness and safety of primary prophylaxis of G-CSF during chemotherapy for prostate cancer, Japanese clinical guideline for appropriate use of G-CSF: clinical practice guidelines for the use of G-CSF 2022

被引：1

作者：

Kimura, Shoji ^{[1
]}

Shigeta, Keisuke ^{[2
]}

Tamura, Shingo ^{[3
]}

Uchino, Keita ^{[4
]}

Kimura, Takahiro ^{[5
]}

Ozaki, Yukinori ^{[6
]}

Nishio, Hiroshi ^{[7
]}

Tsuchihashi, Kenji ^{[8
]}

Ichihara, Eiki ^{[9
]}

Endo, Makoto ^{[10
]}

Yano, Shingo ^{[11
]}

Maruyama, Dai ^{[12
]}

Yoshinami, Tetsuhiro ^{[13
]}

Susumu, Nobuyuki ^{[14
]}

Takekuma, Munetaka ^{[15
]}

Motohashi, Takashi ^{[16
]}

Ito, Mamoru ^{[8
]}

Baba, Eishi ^{[8
]}

Ochi, Nobuaki ^{[17
]}

Kubo, Toshio ^{[18
]}

Kamiyama, Yutaro ^{[11
]}

Nakao, Shinji ^{[19
]}

Tamura, Shinobu ^{[20
]}

Nishimoto, Hitomi ^{[21
]}

Kato, Yasuhisa ^{[22
]}

Sato, Atsushi ^{[23
]}

Takano, Toshimi ^{[6
]}

Miura, Yuji ^{[24
]}

机构：

[1] Jikei Univ, Sch Med, Kashiwa Hosp, Dept Urol, 163-1 Kashiwashita, Kashiwa, Chiba 2778567, Japan

[2] Keio Univ, Sch Med, Dept Urol, Tokyo, Japan

[3] Natl Hosp Org, Kyushu Med Ctr, Dept Med Oncol, Fukuoka, Japan

[4] NTT Med Ctr Tokyo, Dept Med Oncol, Tokyo, Japan

[5] Jikei Univ, Sch Med, Dept Urol, Tokyo, Japan

[6] Japanese Fdn Canc Res, Canc Inst Hosp, Dept Breast Med Oncol, Tokyo, Japan

[7] Keio Univ, Sch Med, Dept Obstet & Gynecol, Tokyo, Japan

[8] Dept Hematol Oncol & Cardiovasc Med, Fukuoka, Japan

[9] Okayama Univ Hosp, Ctr Clin Oncol, Okayama, Japan

[10] Kyushu Univ, Dept Orthopaed Surg, Fukuoka, Japan

[11] Jikei Univ, Sch Med, Dept Internal Med, Div Clin Oncol Hematol, Tokyo, Japan

[12] Japanese Fdn Canc Res, Canc Inst Hosp, Dept Hematol Oncol, Tokyo, Japan

[13] Osaka Univ, Grad Sch Med, Dept Breast & Endocrine Surg, Osaka, Japan

[14] Int Univ Hlth & Welf, Narita Hosp, Dept Obstet & Gynecol, Chiba, Japan

[15] Shizuoka Canc Ctr, Dept Gynecol, Shizuoka, Japan

[16] Tokyo Womens Med Univ Hosp, Dept Obstet & Gynecol, Tokyo, Japan

[17] Kawasaki Med Sch, Dept Gen Internal Med 4, Okayama, Japan

[18] Okayama Univ Hosp, Dept Allergy & Resp Med, Okayama, Japan

[19] Kanazawa Univ, Inst Med Pharmaceut & Hlth Sci, Fac Med, Dept Hematol, Ishikawa, Japan

[20] Wakayama Med Univ, Dept Hematol Oncol, Wakayama, Japan

[21] Okayama Univ Hosp, Dept Nursing, Okayama, Japan

[22] Shonan Univ Med Sci, Fac Pharmaceut Sci, Dept Drug Informat, Yokohama, Kanagawa, Japan

[23] Hirosaki Univ, Grad Sch Med, Dept Med Oncol, Hirosaki, Aomori, Japan

[24] Toranomon Gen Hosp, Dept Med Oncol, Minato Ku, 2-2-2 Toranomon, Tokyo 1058470, Japan

来源：

INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 29卷 / 05期

关键词：

G-CSF; Prostate cancer; Neutropenia; Cabazitaxel; CABAZITAXEL; MITOXANTRONE; PREDNISONE;

D O I：

10.1007/s10147-024-02501-7

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

BackgroundDocetaxel (DTX) is commonly used as a primary chemotherapy, and cabazitaxel (CBZ) has shown efficacy in patients who are DTX resistant. Primary prophylactic granulocyte colony stimulating factor (G-CSF) therapy is currently used with CBZ treatment in routine clinical care in Japan.MethodsIn this study, we performed a systematic review following the Minds guidelines to investigate the effectiveness and safety of primary prophylaxis with G-CSF during chemotherapy for prostate cancer and to construct G-CSF guidelines for primary prophylaxis use during chemotherapy. A comprehensive literature search of various electronic databases (PubMed, Cochrane Library, and Ichushi) was performed on January 10, 2020, to identify studies published between January 1990 and December 31, 2019 that investigate the impact of primary prophylaxis with G-CSF during CBZ administration on clinical outcomes.ResultsUltimately, nine articles were included in the qualitative systematic review. Primary G-CSF prophylaxis during CBZ administration for metastatic castration-resistant prostate cancer was difficult to assess in terms of correlation with overall survival, mortality from infection, and patients' quality of life. These difficulties were owing to the lack of randomized controlled trials comparing patients with and without primary prophylaxis of G-CSF during CBZ administration. However, some retrospective studies have suggested that it may reduce the incidence of febrile neutropenia.ConclusionG-CSF may be beneficial as primary prophylaxis during CBZ administration for metastatic castration resistant prostate cancer, and we made a "weak recommendation to perform" with an annotation of the relevant regimen.

引用

页码：559 / 563

页数：5